Session 4: Preclinical Studies of Novel Therapies

Saturday, September 13, 2025

15:40 - 17:10 CEST

Location: ICE, Auditorium Hall (S1), Entrances On Level 0 & 1

Co-Chair(s)

Paolo Ghia, MD, PhD

Professor of Medical Oncology
Università Vita Salute and IRCCS Ospedale San Raffaele
Milano, Lombardia, Italy
Shih-Shih Chen, PhD

Assistant Professor
The Feinstein Institutes for Medical Research
Manhasset, New York, United States

Presentations:

15:40 - 15:55 CEST

Exploring Siglec-6 as a novel target for potential therapeutic utility in chronic lymphocytic leukemia
Speaker: Natarajan (Raj) Muthusamy, DVM, PhD – The Ohio State University
15:55 - 16:10 CEST

Using Mouse Models to Test Therapeutic Strategies in Richter Transformation
Speaker: Elisa ten Hacken, PhD – Weill Cornell Medicine
16:10 - 16:25 CEST

Lessons from Solid Tumors for CLL: Harnessing B Cells Inside and Outside of Tertiary Lymphoid Structures for New Therapeutics
Speaker: Tullia Bruno, PhD – The University of Pittsburgh Hillman Cancer Center
16:25 - 16:35 CEST

Targeted Degradation of NF-κB RelA/p65 by PBD-Based PROTACs as a Novel Therapeutic Strategy in Chronic Lymphocytic Leukaemia
Primary Author / Presenter: Chris Pepper, PhD – Brighton and Sussex Medical School
16:35 - 16:45 CEST

Zelebrudomide (NX-2127) is a cereblon-modulating BTK degrader that reverses immune dysfunction and modifies both T-cell and CLL-cell transcriptional signatures in patients with CLL
Primary Author / Presenter: Tiana Huynh, MS – City of Hope - Irell and Manella Graduate School of Biological Sciences
16:45 - 16:50 CEST

CLECL1⁺ Proliferative CLL Cells Remodel the Lymph Node Microenvironment Through Fibroblast Reprogramming, Th2 Polarization, and M2 Macrophage Induction to Promote Immune Evasion and Disease Progression
Primary Author / Presenter: Shih-Shih Chen, PhD – The Feinstein Institutes for Medical Research
16:50 - 16:55 CEST

Targeting Lysosomes in the Chronic Lymphocytic Leukemia Microenvironment
Primary Author / Presenter: Madhumita Manivannan – University of Alberta
16:55 - 17:10 CEST

Panel Discussion